Children's Medical Center
Dallas, Texas, 75390, United States
NCT Number: NCT04090892
This research project is being conducted to investigate changes in secondary impairments, functional mobility skills, and gait variables in children with spasticity following selective percutaneous myofascial lengthening. The research project proposed here will be the first to use instrumented three-dimensional motion analysis to investigate the effects of selective percutaneous myofascial lengthening on gait kinematics and kinetics. The objectives of the study are to:
1. Compare gait kinematics and kinetics in children and young adults with lower extremity spasticity before and after selective percutaneous myofascial lengthening to determine the effects of this procedure on functional mobility. 2. Identify changes in impairments and activity limitations following selective percutaneous myofascial lengthening . 3. Identify changes in a family or caregivers perceived quality of life after their child's selective percutaneous myofascial lengthening .
The aim of this study is to identify and describe the specific changes in secondary musculoskeletal impairments, activity limitations, and gait kinematics and kinetics after a selective percutaneous myofascial lengthening procedure. Gait kinematics and kinetics includes the motion of joints and body segments, and force and power, at each lower extremity joint, respectively. The results of this study will provide preliminary information on how this form of soft tissue lengthening affects functional mobility skills in children with spasticity. The study is expected to run for two years and the primary study endpoint is when participants have completed their second post- operative data collection session.
Looking for future studies?
Notify Me4 year–21 year
All sexes
Observational
Dallas, Texas, 75390, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Children will be evaluated before and two times after they undergo a selective percutaneous myofascial release. Investigators make no determination about the need for the surgery or which muscles are released, nor do they participate in the surgery. The investigators are assess outcomes on gait and motor function.
Time frame: Outcomes measures will be administered 4 weeks before surgery as a baseline
Lower extremity joint angles at baseline before
Time frame: Outcomes measures will be administered then at 6 weeks after surgery to assess short term change
Lower extremity joint angles after surgery
Time frame: Outcomes measures will be administered 6 months after surgery to assess long term change.
Lower extremity joint angles after surgery
Time frame: Outcomes measures will be administered 4 weeks before surgery as a baseline
Measures level of gross motor ability
Time frame: Outcomes measures will be administered at 6 weeks after surgery to assess short term change
Measures level of gross motor ability
Time frame: Outcomes measures will be administered at 6 months after surgery to assess long term change.
Measures level of gross motor ability
University of Texas Southwestern Medical Center
Other
Effects of Selective Percutaneous Muscle Lengthening on Gait in Children With Spasticity
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07698639
Brain Diseases, Cardiovascular Diseases
Samara, Samara Oblast, Russia
View Trial DetailsNCT06117020
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
San Antonio, Texas, United States
View Trial DetailsNCT06536751
Brain Damage, Chronic, Brain Diseases
São Paulo, Brazil
View Trial DetailsNCT07002463
Brain Diseases, Cardiovascular Diseases
Wroclaw, Poland
View Trial Details